Litman Gregory Wealth Management LLC Acquires 31,997 Shares of Edwards Lifesciences Co. (NYSE:EW)

Litman Gregory Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 24.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,371 shares of the medical research company’s stock after acquiring an additional 31,997 shares during the period. Litman Gregory Wealth Management LLC’s holdings in Edwards Lifesciences were worth $10,649,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Crewe Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $29,000. Riverview Trust Co acquired a new stake in Edwards Lifesciences in the 1st quarter worth approximately $34,000. Webster Bank N. A. acquired a new stake in Edwards Lifesciences in the 2nd quarter worth approximately $39,000. Finally, Peoples Bank KS acquired a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $40,000. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,250 shares of company stock valued at $1,099,238. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.99 during trading on Wednesday, reaching $70.23. The company had a trading volume of 1,168,659 shares, compared to its average volume of 4,546,851. The firm’s 50-day simple moving average is $67.96 and its 200 day simple moving average is $78.76. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market capitalization of $42.32 billion, a PE ratio of 29.84, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter last year, the company earned $0.66 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research note on Monday, July 29th. Piper Sandler lowered their target price on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $85.00 to $70.00 in a research report on Wednesday, September 18th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Fifteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $75.81.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.